Efficacy and safety studies of frexalimab (SAR441344) in adults with relapsing forms of multiple sclerosis

Phase 1

• Conditions: multiple sclerosis; MedDRA version: 20.1Level: PTClassification code: 10028245Term: Multiple sclerosis Class: 100000004852; Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

• Registration Number: CTIS2023-504358-36-00
• Lead Sponsor: Sanofi-Aventis Recherche & Developpement

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2024-01-08
• Last Update Posted: 22 July 2024

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 1639

Inclusion Criteria

The participant must have been diagnosed with RMS according to the 2017 revision of the McDonald diagnostic criteria., The participant has an EDSS score =5.5 at the first visit (Screening Visit), The participant must have at least 1 of the following prior to screening: ? =1 documented relapse within the previous year OR ? =2 documented relapses within the previous 2 years, OR ? =1 documented Gd enhancing lesion on an MRI scan within the previous year., Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

Exclusion Criteria

The participant has been diagnosed with PPMS according to the 2017 revision of the McDonald diagnostic criteria, The participant has a history of infection or may be at risk for infection., The presence of psychiatric disturbance or substance abuse., History, clinical evidence, suspicion or significant risk for thromboembolic events, as well as myocardial infarction, stroke, and/or antiphosholipid syndrome and any participants requiring antithrombotic treatment., History or current hypogammaglobulinemia defined by values below the lower limit of normal (LLN)., A history or presence of disease that can mimic MS symptoms, such as, but not limited to neuromyelitis optica spectrum disorder, systemic lupus erythematosus, Sjogren’s syndrome, acute disseminated encephalomyelitis, and myasthenia gravis., The participant has had a relapse in the 30 days prior to randomization., The participant has contraindication for MRI, ie, presence of pacemaker, metallic implants in high risk areas (ie, artificial heart valves, aneurysm/vessel clips), presence of metallic material (eg, shrapnel) in high risk areas, known history of allergy to any contrast medium, or history of claustrophobia that would prevent completion of all protocol scheduled MRI scans.

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified